Netrin-1 and its receptors in tumorigenesis

Nature Reviews Cancer

Volumn 4, Issue 12, 2004, Pages 978-987

  Arakawa, Hirofumi ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; NETRIN; NETRIN 1; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CARCINOGENESIS; DCC GENE; GENE INACTIVATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UNC5 GENE; UNC5A GENE; UNC5B GENE; UNC5C GENE; UNC5D GENE; UNC5H1 GENE; UNC5H2 GENE; UNC5H3 GENE; UNC5H4 GENE;

AXONS; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; GENES, DCC; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASMS; NERVE GROWTH FACTORS; RECEPTORS, CELL SURFACE; TUMOR SUPPRESSOR PROTEINS;

EID: 10344239412     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1504     Document Type: Review

References (92)

1. Fearon, E. R. et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49-56 (1990). An Important paper that reported cloning of DCC as a tumour-suppressor gene at chromosome 18q, where frequent deletions are observed in colorectal cancer.
2. Fazeli, A. et al. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 386, 796-804 (1997). This was the first paper to report the knockout of DCC, DCC-knockout mice did not show increased tumour susceptibility.
3. Keino-Masu, K. et al. Deleted In Colorectal Cancer (DCC) encodes a netrin receptor. Cell 87, 175-185 (1996). The first report that demonstrated the function of DCC as a netrin-1 receptor.
4. Tessier-Lavigne, M. & Goodman, C. S. The molecular biology of axon guidance. Science 274, 1123-1133 (1996).
5. Yu, T. W. & Bargmann, C. I. Dynamic regulation of axon guidance. Nature Neurosci. 4, 1169-1176 (2001).
6. Fearon, E. R. DCC; is there a connection between tumorigenesis and cell guidance molecules? Biochim. Biophys. Acta 1288, M17-M23 (1996).
7. Roush, W. Putative cancer gene shows up in development instead. Science 276, 534-535 (1997).
8. Mehlen, P. et al. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395, 801-804 (1998). This important paper provided clear evidence for the first time that DCC regulates apoptosis as a dependence receptor.
9. Serafini, T. et al. The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6. Cell 78, 409-424 (1994).
10. Hedgecook, E. M., Culotti, J. G. & Hall, D. H. The unc-5, unc-6 and unc-40 genes guide circumferential migration of pioneer axons and mesodermal cells on the epidermis of C. elegans. Neuron 2, 61-85 (1990).
11. Ishii, N., Wadsworth, W. G., Stern, B. D., Culotti, J. G. & Hedgecook, E. M. UNC-6, a laminin-related protein, guides cell and pioneer axon migrations in C. elegans. Neuron 9, 873-881 (1992).
12. Kennedy, T. E., Serafini, T., de la Torre, J. R. & Tessier-Lavigne, M. Netrins are diffusible chemotropic factors for commissural axons in the embryonal spinal cord. Cell 78, 425-435 (1994).
13. Chan, S. S. et al. UNC40, a C. elegans homolog of DCC (Deleted in Colorectal Cancer), is required in motile cells responding to UNC-6 netrin cues. Cell 87, 187-195 (1996).
14. Serafini, T. et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell 87, 1001-1014 (1996).
15. Meyerhardt, J. A. et al. Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas. Cell Growth Differ. 10, 35-42 (1999).
16. Latil, A. et al. Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int. J. Cancer 103, 306-315 (2003).
17. Hedrick, L. et al. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. 8, 1174-1183 (1994).
18. Reale, M. A. et al. Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res. 54, 4493-4501 (1994).
19. Thiagalingam, S. et al. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nature Genet. 13, 343-346 (1996).
20. Murty, V. V. et al. Frequent allelic deletions and loss of expression characterize the DCC gene male germ cell tumors. Oncogens 9, 3227-3231 (1994).
21. Hilgers, W. et al. Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers. Genes Chromosomes Cancer 27, 353-357 (2000).
22. Marra, G. & Boland, C. R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J. Natl Cancer Inst. 87, 1114-1125 (1995).
23. Ekstrand, B. C. et al. DCC expression is altered by multiple mechanisms in brain tumours. Oncogene 11, 2393-2402 (1995).
24. Sato, K. et al. Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br. J. Cancer 85, 199-203 (2001).
25. Uchino, S. et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res. 52, 3099-3102 (1992).
26. Hohne, M. W., Halatsch, M. E., Kahl, G. F. & Weinel, R. J. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res. 52, 2616-2619 (1992).
27. Seymour, A. B. et al. Allelotype of pancreatic adenocarcinoma. Cancer Res. 54, 2761-2764 (1994).
28. Hahn, S. A. et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 55, 4670-4675 (1995).
29. Miyake, S. et al. Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res. 54, 3007-3010 (1994).
30. Gao, X., Honn, K., Grignon, D., Sakr, W. & Chen, Y. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic tumors. Cancer Res. 53, 2723-2727 (1993).
31. Latil, A. et al. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 11, 119-125 (1994).
32. Brewster, S. F., Gingell, J. C., Browne, S. & Brown, K. W. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br. J. Cancer 70, 697-700 (1994).
33. Thompson, A. M. et al. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br. J. Cancer 68, 64-68 (1993).
34. Murty, V. V. et al. Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene 9, 3227-3231 (1994).
35. Reale, M. A. et al. Loss of DCC expression in neuroblastoma is associated with disease dissemination. Clin. Cancer Res. 2, 1097-1102 (1996).
36. Ekstrand, B. C., Mansfield, T. A., Bigner, S. H. & Fearon, E. R. DCC expression is altered by multiple mechanism in brain tumors. Oncogene 11, 2393-2402 (1995).
37. Miyake, K., Inokuchi, K., Dan, K. & Nomura, T. Alterations in the deleted in colorectal carcinoma gene in human primary leukemias. Blood 82, 927-930 (1993).
38. Porfiri, E., Seeker-Walker, L., Hoffbrand, A. & Hancock, J. DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18. Blood 81, 2696-2701 (1993).
39. Miyake, K., Inokuchi, K., Dan, K. & Nomura, T. Expression of the DCC gene in myelodysplastic syndromes and overt leukemia. Leukemia Res. 17, 785-788 (1993).
40. Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
41. Riggins, G. J. et al. Mad-related genes in the human. Nature Genet. 13, 347-349 (1996).
42. Tanaka, K. et al. Suppression of tumorigenicity in human colorectal carcinoma cells by introduction of normal chromosome 5 or 18. Nature 349, 340-342 (1991).
43. Narayanan, R. et al. Antisense RNA to the putative tumor suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7, 553-561 (1992).
44. Klingelhutz, A. J., Hedrick, L., Cho, K. R. & McDougall, J. K. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10, 1581-1586 (1995).
45. Leonardo, E. D. et al. Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors. Nature 386, 833-838 (1997).
46. Thiebault, K. et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc. Natl Acad. Sci. USA 100, 4173-4178 (2003). The first paper to report the frequent alterations of the UNC5H family of proteins in human cancers and their roles as tumour suppressors.
47. Sekido, Y. et al. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc. Natl Acad. Sci. USA 93, 4120-4125 (1996).
48. Kuroki, T. et al. Allelic loss on choromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res. 63, 3352-3355 (2003).
49. Tomizawa, Y. et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc. Natl Acad. Sci. USA 98, 13954-13959 (2001).
50. Tse, C., Xiang, R. H., Bracht, T. & Naylor, S. L. Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res. 62, 542-546 (2002).
51. Xiang, R. et al. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res. 62, 2637-2643 (2002).
52. Kessler, O. et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 64, 1008-1015 (2004).
53. Brambilla, E., Constantin, B., Drabkin, H. & Roche, J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am. J. Pathol. 156, 939-950 (2000).
54. Lantuejoul, S. et al. Expression of VEGF, semaphoring SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumors, and cell lines. J. Pathol. 200, 336-347 (2003).
55. Dallol, A., Morton, D., Maher, E. R. & Latif, F. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 63, 1054-1058 (2003).
56. Dallol, A. et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 62, 5874-5880 (2002).
57. Huebner, K. Tumor suppressors on 3p: a neoclassic quartet. Proc. Natl Acad. Sci. USA 98, 14763-14765 (2001).
58. Dallol, A. et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogens 21, 3020-3038 (2002).
59. Sundaresan, V. Homozygous deletions at 3p12 in breast and lung cancer. Oncogene 17, 1723-1729 (1998).
60. Ikegaki, N. et al. Molecular characterization and chromosomal localization of DRT (EPHT3); a developmentally regulated human protein-tyrosine kinase gene of the EPH family. Hum. Mol. Genet. 4, 2033-2045 (1995).
61. Huusko, P. et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genet. 36, 979-983 (2004).
62. Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphoring receptors: cell signaling for invasive growth. Nature Rev. Cancer 2, 289-299 (2002).
63. Tamagnone, L. & Comoglio, P. M. To move or not to move? EMBO Rep. 5, 356-361 (2004).
64. Nakada, M. et al. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 64, 3179-3185 (2004).
65. Roush, W. Receptor links blood vessels, axons. Science 279, 2042 (1998).
66. Liu, Z. J. & Herlyn, M. Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell 4, 1-2 (2004).
67. Wang, B. et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4, 19-29 (2004).
68. Bredesen, D. E., Mehlen, P. & Rabizaheh, S. Apoptosis and dependence receptors: a molecular basis for cellular addiction. Physiol. Rev. 84, 411-430 (2004).
69. Mehlen, P. & Bredesen, D. E. The dependence receptor hypothesis. Apoptosis 9, 37-49 (2004). References 68 and 69 are excellent and important reviews that introduce a new concept 'dependence receptor' to the field of cell death and provide the mechanistic data to support the new roles of 'dependence receptors' in apoptosis regulation.
70. Forcet, C. et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc. Natl Acad. Sci. USA 98, 3415-3421 (2001) This paper clearly demonstrates that DCC-induced apoptosis is independent of both the mitochondrial apoptotic pathway and the death receptor/caspase-8 pathway.
71. Liu, J. et al. Mediation of the DCC apoptotic signal by DIP13α. J. Biol. Chem. 277, 26281-26285 (2002).
72. Llambi, F. et al. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J. 20, 2715-2722 (2001). This was the first paper to report the role of the UNC5H family as dependence receptors and their involvement in apoptosis regulation.
73. Mehlen, P. & Bredesen, D. E. Meeting report: cellular dependence - old concept, new mechanisms. Sci. STKE 2003, pe55 (2003).
74. Williams, M. E., Strickland, P., Watanabe, K. & Hinck, L. UNC5H1 induces apoptosis via its juxtamembrane region through an interaction with NARGE. J. Biol. Chem. 278, 17483-17490 (2003).
75. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401-410 (2002).
76. Mehlen, P. & Thibert, C. Dependence receptors: between life and death. Cell. Mol. Life Sci. 61, 1854-1866 (2004).
77. Hong, K. et al. A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell 97, 927-941 (1999).
78. Wang, J. J. et al. Dimerization-dependent block of the proapoptotic effect of p75/NTR. J. Neurosci. Res. 60, 587-593 (2000).
79. Mitsuuchi, Y. et al. Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/ threonine kinase AKT2. Oncogene 18, 4891-4898 (1999).
80. Dudek, H. et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661-665 (1997).
81. Hemmings, B. A. Akt signaling: linking membrane events to life and death decisions. Science 275, 628-630 (1997).
82. Forcet, C. et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MARK activation. Nature 417, 443-447 (2002).
83. Erhardt, P., Schremser, E. J. & Cooper, G. M. B-raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19, 5308-5315 (1999).
84. Vousden, K. H. p53: death star. Cell 103, 691-694 (2000).
85. Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y. & Arakawa, H. p53RDL1 regulates p53-dependent apoptosis. Nature Cell Biol. 5, 216-223 (2003). Demonstrated the involvement of p53 in netrin-1 regulation and showed that UNC5B mediates p53-dependent apoptosis as a transcriptional target, but that UNC5B blocks p53-induced apoptosis in the presence of netrin-1.
86. Shekarabi, M. & Kennedy, T. E. The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. Mol. Cell. Neurosci. 19, 1-17 (2002).
87. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
88. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
89. Kern, S. E. et al. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 261, 3099-3103 (1989).
90. Mazelin, L. et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 431, 80-84 (2004).
91. Smits, R. et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmold tumors and cutaneous cysts. Gastroenterology 114, 275-283 (1998).
92. Ochi, K., Mori, T., Toyama, Y., Nakamura, Y. & Arakawa, H. Identification of semaphorin3B as a direct target of p53. Neoplasia 4, 82-87 (2002).